Sunday, November 8, 2026

GBP/EUR Slides By 1% In The Last 21 Sessions

ViaNews Editorial Team

February 19, 2023

GBP/EUR Slides By 1% In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.52% for the last 21 sessions. At 14:09 EST on Sunday, 19 February, GBP/EUR (GBPEUR) is $1.13.

GBP/EUR's yearly highs and lows, it's 4.134% up from its 52-week low and 7.614% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.17%, a negative 0.01%, and a positive 0.32%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.17% (last week), 0.36% (last month), and 0.32% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy price analysis: climbs to fresh YTD top, seems poised to appreciate further. According to FXStreet on Friday, 17 February, "The latter marks the 38.2% Fibonacci retracement level of the recent sharp pullback from over a three-decade higher touched in October and should now act as a strong near-term base for the USD/JPY pair.", "On the flip side, the USD/JPY pair seems poised to climb towards the 135.55-135.60 horizontal zone and eventually aim to reclaim the 136.00 mark. "
  • Usd/jpy picks up bids above 134.00 as boj vs. fed battle intensifies amid strong yields. According to FXStreet on Friday, 17 February, "Elsewhere, the fresh US-China tension and Russia's refrain from stepping back when it comes to attacking Ukraine also weigh on the risk appetite and the USD/JPY prices, due to the US Dollar's safe-haven demand. ", "Looking forward, USD/JPY buyers are likely to keep the reins and may propel the price towards refreshing the multi-day high above 134.00 amid a lack of major data/events on the calendar, other than what's already mentioned above."
  • Usd/jpy to slide toward 125 in three months – danske bank. According to FXStreet on Friday, 17 February, "We expect USD/JPY to drop to 125 in 3M following more tightening of monetary policy.", "The development in BoJ's monetary policy stance is still important to follow regarding USD/JPY +3M; however, it is difficult to imagine any changes in the monetary policy until at least April 28th, when the new governor will have his first monetary policy meeting."
  • Eur/usd to reach 1.14, usd/jpy to sink toward 121 by year-end – BNP paribas. According to FXStreet on Friday, 17 February, "Economists at BNP Paribas Research revise their targets on EUR/USD and USD/JPY as they expect the Dollar to embark on a bearish trend.", "With evidence of these repatriation flows appearing, we revise our USD forecasts lower and now project EUR/USD to rise to 1.14 by end-2023 and USD/JPY to decline to 121."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com